If there's a positive message to take away from the FDA's seemingly endless troubles in 2005, it may be that smaller companies are increasingly registering on the agency's radar.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fox, J. Nat. Biotechnol. 23, 1327–1328 (2005).
Kling, J. Nat. Biotechnol. 23, 1325 (2005).
Sheridan, C. Nat. Biotechnol. 23, 397–398 (2005).
Tsang, L. Nat. Biotechnol. 23, 1050–1053 (2005).
Author information
Author notes
Mark Ratner is a freelance writer based in Cambridge, Massachusetts, USA.
- Mark Ratner
Rights and permissions
About this article
Cite this article
Ratner, M. A turbulent year at the agency. Nat Biotechnol 24, 145–151 (2006). https://doi.org/10.1038/nbt0206-145
Issue Date:
DOI: https://doi.org/10.1038/nbt0206-145
This article is cited by
-
Despite glacial progress, US government signals support for personalized medicine
Nature Biotechnology (2007)